

Newsletter

Klinische Studien

Liebe Kolleginnen und Kollegen,
in unserem Update ‚Klinische Studien‘ stellen wir Ihnen regelmäßig ausgewählte, hämatologische und onkologische, aktuell rekrutierende Studien vor, die am UKSH und von unseren Netzwerkpartnern angeboten werden. Damit möchten wir die Rekrutierung Ihrer und unserer Studien unterstützen und das Studienangebot im Netzwerk erweitern.

Kontakt UCCSH: Dr. Christina Schwitlick ✉ christina.schwitlick@uksh.de

Eine Übersicht über alle derzeit rekrutierenden Studien finden Sie unter <https://www.quickqueck.de>

new

akute myeloische Leukämie (AML)

MOSAIC Phase I/II Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia

Indikation Newly diagnosed AML

Campus Kiel Dr. med. Lars Fransecky ✉ lars.fransecky@uksh.de ☎ 0431 500-22 515

Diffuses großzelliges B-Zell-Lymphom

R-Pola-Glo Phase II Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Indikation aggressive B-cell lymphoma, not eligible for a fully dosed R-CHOP

Campus Lübeck PD Dr. med. Niklas Gebauer ✉ niklas.gebauer@uksh.de ☎ 0451 500-75640

Campus Kiel Prof. Dr. Christiane Pott ✉ christiane.pott@uksh.de ☎ 0431 500-22516

Multiples Myelom

HDP-101-01 Phase I/II A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma

Indikation active MM, undergone SCT or is considered transplant ineligible, undergone prior treatments

Campus Lübeck Prof. Cyrus Khandanpour ✉ cyrus.khandanpour@uksh.de ☎ 0451 500-44152

Campus Kiel Dr. med. Natalie Schub ✉ natalie.schub@uksh.de ☎ 0431 500-22711

Adenokarzinom des Gastroösophagealen Übergangs

FORTITUDE-102 Phase Ib/III A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Indikation unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Campus Kiel Prof. Dr. Anne Letsch ✉ anne.letsch@uksh.de ☎ 0431 500-22510

nicht-kleinzelliges Lungenkarzinom
ANTELOPE Phase IV Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma

Indikation Histologically or cytologically confirmed metastatic stage IV non-squamous NSCLC, neg. TTF-1, neg. EGFR mutations and ALK rearrangements

Campus Lübeck Dr. med. Sabine Bohnet ✉ sabine.bohnet@uksh.de ☎ 0451 500-45001

nicht-kleinzelliges Lungenkarzinom
AVANZAR Phase III A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecán (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Indikation Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease, no actionable genomic alterations

Städtisches Krankenhaus Kiel Prof. Dr. Roland Repp ✉ roland.repp@krankenhaus-kiel.de ☎ 0431 1697-1201

Kolon-/Rektumkarzinom
CIRCULATE Phase III Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation

Indikation Resected colon cancer stage II, Resected rectal cancer stage II, no indication for radiotherapy

Campus Lübeck Dr. med. Kim Luley ✉ kim.luley@uksh.de ☎ 0451 500-44153

Städtisches Krankenhaus Kiel Dr. med. Alexander Leins ✉ alexander.leins@krankenhaus-kiel.de ☎ 0431 1697-5630

HER-2 negativer Brustkrebs
EMBER-4 Phase III A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

Indikation ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis

Campus Kiel PD Dr. med. Marion van Mackelenbergh ✉ MarionTina.vanMackelenbergh@uksh.de ☎ 0431 500-21410

Melanom
R3767-ONC-2011 Phase II/III A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Indikation unresectable Stage III and Stage IV (metastatic) melanoma, no prior systemic therapy for advanced unresectable disease

Campus Lübeck Prof. Dr. Patrick Terheyden ✉ Patrick.Terheyden@uksh.de ☎ 0451 500-41510

Campus Kiel Prof. Dr. Axel Hauschild ✉ ahauschild@dermatology.uni-kiel.de ☎ 0431 500-21130

Melanom, adjuvant

**R3767-
ONC-2055** A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
Phase III

Indikation stage IIB, IIC, III, or stage IV histologically confirmed melanoma that is completely surgically resected

Campus Kiel Prof. Dr. Axel Hauschild ✉ ahauschild@dermatology.uni-kiel.de ☎ 0431 500-21130

Multiples Myelom

BELI(E)VE Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (Phase I/IIa)
Phase I/II

Indikation Multiple Myeloma, ECOG ≤ 2

Campus Lübeck Prof. Cyrus Khandanpour ✉ cyrus.khandanpour@uksh.de ☎ 0451 500-44152